{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:43:12Z","timestamp":1792089792453,"version":"4.4.0"},"reference-count":151,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UQ Research Support Fellowship","award":["2010053"],"award-info":[{"award-number":["2010053"]}]},{"name":"the National health and Medical Research Council of Australia","award":["2010053"],"award-info":[{"award-number":["2010053"]}]},{"name":"Mater Foundation","award":["2010053"],"award-info":[{"award-number":["2010053"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Type 1 diabetes (T1D) is an autoimmune disease in which the \u03b2-cells of the pancreas are attacked by the host\u2019s immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with increasing prevalence of T1D in genetically stable populations, highlighting an environmental component, consumption of advanced glycation end products (AGEs) commonly found in in Western diets has increased significantly over the past decades. AGEs can bind to cell surface receptors including the receptor for advanced glycation end products (RAGE). RAGE has proinflammatory roles including in host\u2013pathogen defense, thereby influencing immune cell behavior and can activate and cause proliferation of immune cells such as islet infiltrating CD8+ and CD4+ T cells and suppress the activity of T regulatory cells, contributing to \u03b2-cell injury and hyperglycemia. Insights from studies of individuals at risk of T1D have demonstrated that progression to symptomatic onset and diagnosis can vary, ranging from months to years, providing a window of opportunity for prevention strategies. Interaction between AGEs and RAGE is believed to be a major environmental risk factor for T1D and targeting the AGE-RAGE axis may act as a potential therapeutic strategy for T1D prevention.<\/jats:p>","DOI":"10.3390\/cells11213503","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T02:43:51Z","timestamp":1667789031000},"page":"3503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development"],"prefix":"10.3390","volume":"11","author":[{"given":"Chenping","family":"Du","sequence":"first","affiliation":[{"name":"Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia"},{"name":"School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-5519","authenticated-orcid":false,"given":"Rani O.","family":"Whiddett","sequence":"additional","affiliation":[{"name":"Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-3509","authenticated-orcid":false,"given":"Irina","family":"Buckle","sequence":"additional","affiliation":[{"name":"Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia"},{"name":"Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2104-534X","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-8174","authenticated-orcid":false,"given":"Josephine M.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia"},{"name":"Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia"},{"name":"Department of Medicine, The University of Melbourne, Austin Health, Heidelberg 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-8923","authenticated-orcid":false,"given":"Amelia K.","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia"},{"name":"Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis","volume":"10","author":"Mobasseri","year":"2020","journal-title":"Health Promot. Perspect."},{"key":"ref_2","first-page":"294","article-title":"Type 1 Diabetes Mellitus: Cellular and Molecular Pathophysiology at a Glance","volume":"20","author":"Karamzadeh","year":"2018","journal-title":"Cell J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-Onset Type 1 Diabetes: Current Understanding and Challenges","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","article-title":"Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: Results of a multicentre double-blind trial","volume":"2","author":"Feutren","year":"1986","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11892-017-0878-z","article-title":"Combination Immunotherapy for Type 1 Diabetes","volume":"17","author":"Bone","year":"2017","journal-title":"Curr. Diabetes Rep."},{"key":"ref_9","unstructured":"Australian National Diabetes Audit (2019). Australian National Diabetes Audit\u2014Australian Quality Clinical Audit 2019 Annual Report."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2174\/1573399812666160427104157","article-title":"Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?","volume":"13","author":"Fousteri","year":"2017","journal-title":"Curr. Diabetes Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/pedi.12545","article-title":"Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity","volume":"19","author":"Ilonen","year":"2018","journal-title":"Pediatr. Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/jc.2006-1494","article-title":"Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity","volume":"92","author":"Wang","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-021-03552-w","article-title":"Interpreting type 1 diabetes risk with genetics and single-cell epigenomics","volume":"594","author":"Chiou","year":"2021","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.intimp.2014.06.033","article-title":"Role of immune system in type 1 diabetes mellitus pathogenesis","volume":"22","author":"Szablewski","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1172\/JCI94549","article-title":"Autoreactive T cells in type 1 diabetes","volume":"127","author":"Pugliese","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.52.4.1052","article-title":"Genetic Liability of Type 1 Diabetes and the Onset Age Among 22,650 Young Finnish Twin Pairs: A Nationwide Follow-Up Study","volume":"52","author":"Hyttinen","year":"2003","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1056\/NEJMc0805398","article-title":"Concordance for Islet Autoimmunity among Monozygotic Twins","volume":"359","author":"Redondo","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"1","article-title":"Breeding of a non-obese, diabetic strain of mice","volume":"29","author":"Makino","year":"1980","journal-title":"Jikken Dobutsu"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fendo.2018.00051","article-title":"The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fendo.2017.00343","article-title":"T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes","volume":"8","author":"Burrack","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell Tolerance: Central and Peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"a007807","DOI":"10.1101\/cshperspect.a007807","article-title":"Breakdown in peripheral tolerance in type 1 diabetes in mice and humans","volume":"2","author":"Jeker","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MED.0000000000000646","article-title":"Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes","volume":"28","author":"Erdem","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","article-title":"Environmental risk factors for type 1 diabetes","volume":"387","author":"Rewers","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fendo.2019.00592","article-title":"Environmental Factors Associated with Type 1 Diabetes","volume":"10","author":"Esposito","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/pedi.12597","article-title":"Genetics of type 1 diabetes","volume":"19","author":"Redondo","year":"2018","journal-title":"Pediatr. Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00125-019-05032-3","article-title":"Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes","volume":"63","author":"Claessens","year":"2020","journal-title":"Diabetologia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/diacare.27.12.2784","article-title":"Diet, growth, and the risk for type 1 diabetes in childhood: A matched case-referent study","volume":"27","author":"Persson","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2337\/diacare.26.10.2865","article-title":"Testing the Accelerator Hypothesis: The relationship between body mass and age at diagnosis of type 1 diabetes","volume":"26","author":"Kibirige","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00125-005-0033-2","article-title":"The \u2018accelerator hypothesis\u2019: Relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus","volume":"48","author":"Knerr","year":"2005","journal-title":"Diabetologia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00125-020-05358-3","article-title":"Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk","volume":"64","author":"Nucci","year":"2021","journal-title":"Diabetologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"890833","DOI":"10.3389\/fendo.2022.890833","article-title":"Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children\u2014From Disease Pathogenesis to Complications","volume":"13","author":"Kurpiewska","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","article-title":"Current and future therapies for type 1 diabetes","volume":"64","author":"Kreiner","year":"2021","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Holmes-Walker, D.J., Abraham, M.B., Chee, M., and Jones, T.W. (2022). Glycaemic outcomes in Australasian children and adults with type 1 diabetes: Failure to meet targets across the age spectrum. Intern. Med. J., ahead of print.","DOI":"10.1111\/imj.15426"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1399-543X.2006.00155.x","article-title":"\u2018The honeymoon phase\u2019 in children with type 1 diabetes mellitus: Frequency, duration, and influential factors","volume":"7","author":"Habib","year":"2006","journal-title":"Pediatr. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.43.5.667","article-title":"Immunohistochemical Characterization of Monocytes-Macrophages and Dendritic Cells Involved in the Initiation of the Insulitis and \u03b2-Cell Destruction in NOD Mice","volume":"43","author":"Jansen","year":"1994","journal-title":"Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1084\/jem.20111187","article-title":"Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients","volume":"209","author":"Coppieters","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2337\/db07-0416","article-title":"Screening for insulitis in adult autoantibody-positive organ donors","volume":"56","author":"Lievens","year":"2007","journal-title":"Diabetes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/dmrr.2316","article-title":"Network for Pancreatic Organ Donors with Diabetes (nPOD): Developing a tissue biobank for type 1 diabetes","volume":"28","author":"Wasserfall","year":"2012","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4161\/isl.3.4.15728","article-title":"Insulitis in human type 1 diabetes: The quest for an elusive lesion","volume":"3","year":"2011","journal-title":"Islets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/348639a0","article-title":"Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages","volume":"348","author":"Hutchings","year":"1990","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.189.2.347","article-title":"The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice","volume":"189","author":"Jun","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.2337\/db08-1007","article-title":"Big mac attack: Does it play a direct role for monocytes\/macrophages in type 1 diabetes?","volume":"57","author":"Yang","year":"2008","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nri2787","article-title":"Immune cell crosstalk in type 1 diabetes","volume":"10","author":"Lehuen","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo","volume":"194","author":"Hawiger","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1074-7613(03)00120-1","article-title":"Inducible Transgenic Mice Reveal Resting Dendritic Cells as Potent Inducers of CD8+ T Cell Tolerance","volume":"18","author":"Probst","year":"2003","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fimmu.2013.00415","article-title":"Dendritic cell subsets in type 1 diabetes: Friend or foe?","volume":"4","author":"Morel","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/db17-1564","article-title":"Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?","volume":"67","author":"Creusot","year":"2018","journal-title":"Diabetes"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4049\/jimmunol.179.8.5041","article-title":"The Countervailing Actions of Myeloid and Plasmacytoid Dendritic Cells Control Autoimmune Diabetes in the Nonobese Diabetic Mouse","volume":"179","author":"Saxena","year":"2007","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s00125-006-0569-9","article-title":"Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-\u03b1 in patients with recent-onset type 1 diabetes","volume":"50","author":"Uno","year":"2007","journal-title":"Diabetologia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clim.2008.08.013","article-title":"Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood","volume":"129","author":"Chen","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clim.2007.03.002","article-title":"Decreased blood dendritic cell counts in type 1 diabetic children","volume":"123","author":"Vuckovic","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.it.2013.08.005","article-title":"Immune mechanisms in type 1 diabetes","volume":"34","author":"Wallberg","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.2337\/diabetes.53.10.2588","article-title":"Local Activation of Dendritic Cells Leads to Insulitis and Development of Insulin-Dependent Diabetes in Transgenic Mice Expressing CD154 on the Pancreatic \u03b2-Cells","volume":"53","author":"Haase","year":"2004","journal-title":"Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1900\/RDS.2009.6.97","article-title":"Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations","volume":"6","author":"Phillips","year":"2009","journal-title":"Rev. Diabet. Stud."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(00)80178-6","article-title":"The role of Fas in autoimmune diabetes","volume":"89","author":"Chervonsky","year":"1997","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1369\/0022155415576543","article-title":"Heterogeneity and Lobularity of Pancreatic Pathology in Type 1 Diabetes during the Prediabetic Phase","volume":"63","author":"Suwandi","year":"2015","journal-title":"J. Histochem. Cytochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1172\/JCI116835","article-title":"Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients","volume":"92","author":"Itoh","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1600-6143.2011.03844.x","article-title":"Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation in the absence of GAD and IA-2 autoantibodies","volume":"12","author":"Assalino","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E2109","DOI":"10.1210\/jc.2012-1815","article-title":"Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes","volume":"97","author":"Williams","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.2337\/db14-0549","article-title":"Increased immune cell infiltration of the exocrine pancreas: A possible contribution to the pathogenesis of type 1 diabetes","volume":"63","author":"Ekwall","year":"2014","journal-title":"Diabetes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1601118","article-title":"Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?","volume":"197","author":"Visperas","year":"2016","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00125-017-4377-1","article-title":"Regulatory T cell dysfunction in type 1 diabetes: What\u2019s broken and how can we fix it?","volume":"60","author":"Hull","year":"2017","journal-title":"Diabetologia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","volume":"207","author":"Baeyens","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11892-016-0739-1","article-title":"Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2","volume":"16","author":"Dwyer","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e147474","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"722979","DOI":"10.3389\/fimmu.2021.722979","article-title":"Natural Killer Cells as Key Mediators in Type I Diabetes Immunopathology","volume":"12","author":"Gardner","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.2337\/db10-0866","article-title":"Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: The Diabetes and Autoimmunity Study in the Young (DAISY)","volume":"59","author":"Stene","year":"2010","journal-title":"Diabetes"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1096-9071(200006)61:2<214::AID-JMV7>3.0.CO;2-9","article-title":"Enterovirus RNA in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: A prospective study","volume":"61","author":"Salminen","year":"2000","journal-title":"J. Med. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00125-011-2305-3","article-title":"Human enterovirus infections in children at increased risk for type 1 diabetes: The Babydiet study","volume":"54","author":"Pflueger","year":"2011","journal-title":"Diabetologia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/pedi.13205","article-title":"Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic","volume":"22","author":"Ho","year":"2021","journal-title":"Pediatr. Diabetes"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Qeadan, F., Tingey, B., Egbert, J., Pezzolesi, M.G., Burge, M.R., Peterson, K.A., and Honda, T. (2022). The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort from the US using the Cerner Real-World Data. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266809"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jada.2010.03.018","article-title":"Advanced glycation end products in foods and a practical guide to their reduction in the diet","volume":"110","author":"Uribarri","year":"2010","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"16R","DOI":"10.1093\/glycob\/cwi053","article-title":"Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation","volume":"15","author":"Ramasamy","year":"2005","journal-title":"Glycobiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.foodchem.2015.06.049","article-title":"Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database","volume":"190","author":"Scheijen","year":"2016","journal-title":"Food Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.fct.2013.06.052","article-title":"Advanced glycation endproducts in food and their effects on health","volume":"60","author":"Poulsen","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.diabres.2018.11.016","article-title":"Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review","volume":"148","author":"Jud","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1900934","DOI":"10.1002\/mnfr.201900934","article-title":"The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction","volume":"65","author":"Sergi","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1007\/s13197-015-1851-y","article-title":"Advanced glycation End-products (AGEs): An emerging concern for processed food industries","volume":"52","author":"Sharma","year":"2015","journal-title":"J. Food Sci. Technol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12986-018-0306-7","article-title":"Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies","volume":"15","author":"Chen","year":"2018","journal-title":"Nutr. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2337\/dc05-2096","article-title":"Diabetes and advanced glycoxidation end products","volume":"29","author":"Huebschmann","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","article-title":"Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms","volume":"3","author":"Stirban","year":"2014","journal-title":"Mol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1700118","DOI":"10.1002\/mnfr.201700118","article-title":"Dietary advanced glycation end products modify gut microbial composition and partially increase colon permeability in rats","volume":"61","author":"Qu","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/mnfr.201300847","article-title":"Maillard reaction products modulate gut microbiota composition in adolescents","volume":"58","author":"Seiquer","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40168-018-0471-y","article-title":"Thermal processing of food reduces gut microbiota diversity of the host and triggers adaptation of the microbiota: Evidence from two vertebrates","volume":"6","author":"Zhang","year":"2018","journal-title":"Microbiome"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12986-016-0083-0","article-title":"Heat-treated high-fat diet modifies gut microbiota and metabolic markers in apoe\u2212\/\u2212 mice","volume":"13","author":"Marungruang","year":"2016","journal-title":"Nutr. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fendo.2020.00125","article-title":"Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Snelson, M., and Coughlan, M.T. (2019). Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology. Nutrients, 11.","DOI":"10.3390\/nu11020215"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1089\/dia.2011.0034","article-title":"Advanced Glycation End Products, Measured as Skin Autofluorescence and Diabetes Complications: A Systematic Review","volume":"13","author":"Bos","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/db11-0971","article-title":"Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: A twin and population study","volume":"61","author":"Beyan","year":"2012","journal-title":"Diabetes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2337\/db10-1033","article-title":"Advanced glycation end products are direct modulators of beta-cell function","volume":"60","author":"Coughlan","year":"2011","journal-title":"Diabetes"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1210\/en.2008-1342","article-title":"Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis","volume":"150","author":"Zhao","year":"2009","journal-title":"Endocrinology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/19382014.2017.1405189","article-title":"Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction","volume":"10","author":"Borg","year":"2018","journal-title":"Islets"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2337\/diabetes.52.6.1441","article-title":"Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice","volume":"52","author":"Peppa","year":"2003","journal-title":"Diabetes"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/dc10-1058","article-title":"Maternally transmitted and food-derived glycotoxins: A factor preconditioning the young to diabetes?","volume":"33","author":"Mericq","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s00125-011-2058-z","article-title":"Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes","volume":"54","author":"Forbes","year":"2011","journal-title":"Diabetologia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00726-013-1542-9","article-title":"Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects","volume":"46","author":"Forbes","year":"2014","journal-title":"Amino Acids"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11892-013-0453-1","article-title":"Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?","volume":"14","author":"Vlassara","year":"2014","journal-title":"Curr. Diabetes Rep."},{"key":"ref_109","first-page":"101","article-title":"Fatty liver disease in diabetes mellitus","volume":"4","author":"Bhatt","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Barros, B.S.V., Santos, D.C., Pizarro, M.H., del Melo, L.G.N., and Gomes, M.B. (2017). Type 1 Diabetes and Non-Alcoholic Fatty Liver Disease: When Should We Be Concerned? A Nationwide Study in Brazil. Nutrients, 9.","DOI":"10.3390\/nu9080878"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3945\/ajcn.115.125427","article-title":"Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: A double-blind, randomized, crossover trial","volume":"103","author":"Soldatos","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00125-016-4053-x","article-title":"Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: A randomised controlled trial","volume":"59","author":"Vlassara","year":"2016","journal-title":"Diabetologia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.57","article-title":"Targeted reduction of advanced glycation improves renal function in obesity","volume":"80","author":"Harcourt","year":"2011","journal-title":"Kidney Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2013.11.033","article-title":"Dietary glycotoxins exacerbate progression of experimental fatty liver disease","volume":"60","author":"Leung","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","article-title":"Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease","volume":"22","author":"Leung","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fcvm.2020.00037","article-title":"Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights from Human Subjects and Animal Models","volume":"7","author":"Yepuri","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_117","first-page":"403460","article-title":"Receptor for advanced glycation end products and its involvement in inflammatory diseases","volume":"2013","author":"Chuah","year":"2013","journal-title":"Int. J. Inflam."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"Clinical review: The role of advanced glycation end products in progression and complications of diabetes","volume":"93","author":"Goh","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: Sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.str.2011.02.013","article-title":"Advanced glycation end product recognition by the receptor for AGEs","volume":"19","author":"Xue","year":"2011","journal-title":"Structure"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1056-8727(01)00208-2","article-title":"CD36, serves as a receptor for advanced glycation endproducts (AGE)","volume":"16","author":"Ohgami","year":"2002","journal-title":"J. Diabetes Complicat."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00726-003-0029-5","article-title":"Scavenger receptors for oxidized and glycated proteins","volume":"25","author":"Horiuchi","year":"2003","journal-title":"Amino Acids"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"13348","DOI":"10.1074\/jbc.M011613200","article-title":"Scavenger Receptor Class B Type I-mediated Reverse Cholesterol Transport Is Inhibited by Advanced Glycation End Products*","volume":"276","author":"Ohgami","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1074\/jbc.M006545200","article-title":"CD36, a Member of the Class B Scavenger Receptor Family, as a Receptor for Advanced Glycation End Products *","volume":"276","author":"Ohgami","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Pucha\u0142owicz, K., and Ra\u0107, M.E. (2020). The Multifunctionality of CD36 in Diabetes Mellitus and Its Complications\u2014Update in Pathogenesis, Treatment and Monitoring. Cells, 9.","DOI":"10.3390\/cells9081877"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e20211314","DOI":"10.1084\/jem.20211314","article-title":"CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate","volume":"219","author":"Chen","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/BF03401604","article-title":"Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex","volume":"1","author":"Vlassara","year":"1995","journal-title":"Mol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11154-021-09704-7","article-title":"Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot","volume":"23","author":"Li","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbrc.2006.03.105","article-title":"Immune-mediated \u03b2-cell destruction in vitro and in vivo\u2014A pivotal role for galectin-3","volume":"344","author":"Karlsen","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/jcp.24318","article-title":"Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro","volume":"228","author":"Saksida","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2008.08.024","article-title":"Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice","volume":"130","author":"Shahin","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE Signaling in Inflammatory Disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"931473","DOI":"10.3389\/fimmu.2022.931473","article-title":"Pathophysiology of RAGE in inflammatory diseases","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1021\/acs.jmedchem.7b00058","article-title":"Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective","volume":"60","author":"Bongarzone","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","article-title":"A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)","volume":"22","author":"Raucci","year":"2008","journal-title":"FASEB J."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Ebert, H., Lacruz, M.E., Kluttig, A., Simm, A., Greiser, K.H., Tiller, D., Kartschmit, N., and Mikolajczyk, R. (2019). Advanced glycation end products and their ratio to soluble receptor are associated with limitations in physical functioning only in women: Results from the CARLA cohort. BMC Geriatr., 19.","DOI":"10.1186\/s12877-019-1323-8"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/med.21654","article-title":"Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes","volume":"40","author":"Fotheringham","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e2872","DOI":"10.1002\/dmrr.2872","article-title":"A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes","volume":"33","author":"Salonen","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2337\/dc13-3049","article-title":"Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes","volume":"37","author":"Salonen","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2337\/dc14-1186","article-title":"Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes","volume":"38","author":"Salonen","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2337\/dc15-0925","article-title":"Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes","volume":"38","author":"Thomas","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.4049\/jimmunol.179.12.8051","article-title":"Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo","volume":"179","author":"Moser","year":"2007","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/db22-0177","article-title":"Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells","volume":"71","author":"Leung","year":"2022","journal-title":"Diabetes"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","article-title":"RAGE ligation affects T cell activation and controls T cell differentiation","volume":"181","author":"Chen","year":"2008","journal-title":"J. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11596-014-1224-1","article-title":"Advanced glycation end products promote differentiation of CD4+ T helper cells toward pro-inflammatory response","volume":"34","author":"Han","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Akirav, E.M., Preston-Hurlburt, P., Garyu, J., Henegariu, O., Clynes, R., Schmidt, A.M., and Herold, K.C. (2012). RAGE expression in human T cells: A link between environmental factors and adaptive immune responses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034698"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.4049\/jimmunol.1600197","article-title":"The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus","volume":"197","author":"Durning","year":"2016","journal-title":"J. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00125-020-05105-8","article-title":"Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability","volume":"63","author":"Zhang","year":"2020","journal-title":"Diabetologia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/db07-1499","article-title":"Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/21\/3503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:11:03Z","timestamp":1760145063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/21\/3503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":151,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cells11213503"],"URL":"https:\/\/doi.org\/10.3390\/cells11213503","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}